Who Paid My Doc
Michael George
Pediatric Orthopaedic Surgery Houston, TX Medical Doctor
NPI 1235110222 CMS profile 10101
17270 Red Oak Dr, Suite 200, Houston, TX 77090
General payments
$13,370
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Michael George of Houston, TX is reported in the CMS Open Payments database as having received $13,370 across 118 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 82nd percentile of Pediatric Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,392 | 6 | |
| 2024 | General | $631 | 2 | |
| 2023 | General | $217 | 5 | |
| 2022 | General | $223 | 10 | |
| 2021 | General | $7,709 | 41 | |
| 2020 | General | $2,475 | 26 | |
| 2019 | General | $723 | 28 |
Beside peers
- Michael George
- Pediatric Orthopaedic Surgery median
- Middle half of Pediatric Orthopaedic Surgery
- National median
In program year 2025, general payments to Michael George were reported at $1,392. Among 495 Pediatric Orthopaedic Surgery profiles paid that year, the median was $271 and the middle half received between $89 and $1,158.
Show as a table
| Year | Michael George | Pediatric Orthopaedic Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $723 | $355 | $117–$1,889 | $163 |
| 2020 | $2,475 | $290 | $62–$1,625 | $114 |
| 2021 | $7,709 | $628 | $75–$2,400 | $132 |
| 2022 | $223 | $427 | $115–$2,170 | $149 |
| 2023 | $217 | $265 | $98–$1,497 | $160 |
| 2024 | $631 | $255 | $84–$1,694 | $164 |
| 2025 | $1,392 | $271 | $89–$1,158 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 17 drugsPart D claims
2,320
Drug cost
$40,357
Branded share of claims
33.8%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xarelto Rivaroxaban | Brand | 140 | $25,693 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 533 | $5,715 | |
| Celecoxib | Generic | 380 | $4,426 | |
| Meloxicam | Generic | 318 | $929 | |
| Ondansetron Hcl | Generic | 259 | $838 | |
| Acetaminophen-Codeine Acetaminophen With Codeine | Brand | 98 | $786 | |
| Tramadol Hcl | Generic | 199 | $562 | |
| Gabapentin | Generic | 165 | $532 | |
| Nabumetone | Generic | 16 | $299 | |
| Naproxen | Generic | 69 | $237 |
The 10 drugs with the highest cost, of 17 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 47 billing codesPaid by Medicare
$299,737
Medicare patients
477
Services billed
13,448
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Ischemic heart disease | 32% | |
| Diabetes | 31% | |
| Chronic kidney disease | 24% | |
| Depression | 22% | |
| Atrial fibrillation | 17% | |
| Cancer | 16% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Hyaluronan or derivative, gel-one, for intra-articular injection, per dose J7326 | Office | 38 | 72 | $29,191 |
| Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 | Office | 241 | 1,909 | $10,252 |
| Hyaluronan or derivative, trivisc, for intra-articular injection, 1 mg J7329 | Office | 17 | 1,500 | $7,955 |
| Hyaluronan or derivative, durolane, for intra-articular injection, 1 mg J7318 | Office | 16 | 1,560 | $7,294 |
| Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 | Office | 19 | 79 | $4,358 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 | Office | 18 | 128 | $98 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
118 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Orthopaedic Surgery in Texas
Gary Brock
Pediatric Orthopaedic Surgery · Houston, TX
John Heflin
Pediatric Orthopaedic Surgery · El Paso, TX
Jaysson Brooks
Pediatric Orthopaedic Surgery · Dallas, TX
James Bennett
Pediatric Orthopaedic Surgery · The Woodlands, TX
Jaclyn Hill
Pediatric Orthopaedic Surgery · Houston, TX
Brian Kaufman
Pediatric Orthopaedic Surgery · Austin, TX
Related records
Pediatric Orthopaedic Surgery in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Orthopaedic Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.